ClinicalTrials.gg
RecruitingNCT06463743Updated Nov 6, 2026

Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

A Phase 2 interventional study of metformin and Placebo in Multiple Sclerosis, sponsored by State University of New York at Buffalo. Recruiting at 1 site in United States. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by State University of New York at Buffalo · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
55 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Multiple Sclerosis by State University of New York at Buffalo — 1 open to participants now, 1 under way, none of them phase 3. Multiple Sclerosis · State University of New York at Buffalo.

Started
2025
the only one that year
Phase 2
2 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Multiple Sclerosis by State University of New York at Buffalo, this one is the only one that started in 2025, is one of 2 in phase 2, and was the 10th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 10 studies in Multiple Sclerosis by State University of New York at Buffalo is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 55 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Multiple Sclerosis by State University of New York at Buffalo, or all of them as a file.
02

Study summary

The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy. The investigators want to learn:

  • The safety and tolerability of metformin extended release (1500 mg/day) as a single therapy or as an add-on therapy in older people with MS compared to placebo
  • How well metformin protects the nervous system against injury compared with placebo measured by brain MRI over a 9 month treatment period
  • The effect of metformin to protect brain tissue from age and MS related injury when compared to the placebo group over a 9 month treatment period
Read the detailed description

Specific aims and rationale:

The main aim of this study is to determine the safety of metformin as monotherapy or as an add-on therapy to the disease modifying treatment in aging people with multiple sclerosis (pwMS). While the tolerability of metformin has been studies in the general population, data specific to the MS population is not currently available. Moreover, understanding the gastrointestinal tolerability of metformin when added on MS disease modifying treatment is needed. Secondly, the study aims at understating the potential neuroprotective properties of metformin as measured through magnetic resonance spectroscopy and change in N-acetyl-aspartate (NAA) levels over a 9-month study period. This pilot study will provide valuable insights into the efficacy and safety of add-on or monotherapy metformin therapy as a potential therapeutic approach to address the complex pathophysiology of MS and offer new avenues for promoting neuroprotection along with potential support for neural repair and remyelination in individuals with this debilitating condition. Previous pre-clinical studies have shown that metformin can promote neuroprotection by reducing oxidative stress and inflammation and is able to enhance the reparative mechanisms within the central nervous system (CNS). Currently there are no neuroprotective interventions available for pwMS that directly target the neurodegenerative component of MS, with particular emphasis for the aging MS population. The investigators hypothesize that older pwMS that are treated with metformin will have a significantly lower decline in N-acetylaspartate levels when compared to pwMS not treated with metformin.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • metformin
04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age between 55 and 75 years old
  2. having a diagnosis of MS based on the latest McDonald criteria
  3. non-active disease course (no relapses and no MRI activity) in the last 2 years as determined by the MS provider and based on the 2020 revised clinical course criteria
  4. EDSS score \<7.0

Exclusion criteria

Exclusion Criteria:

  1. inability to undergo MRI scans
  2. inability to participate in the study during the study period
  3. diabetes or uncontrolled cardiovascular disease
  4. unable to consent
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    metformin

    metformin

    Drug: metformin

  • Placebo comparator
    placebo

    placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.

    The adverse events (AE) will be collected using standardized Adverse Events Form. The severity of the AE will be determined using 5-level grading system where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of daily living (ADL); Grade 3: Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening consequences; urgent intervention indicated; and Grade 5: Death related to AE. Additional information regarding the relation to the study medication (related/non related), treatment required (none/drug/non-drug) and the outcome of the AE will be recorded

    Time frame: 1 year

  2. Percent change in N-Acetyl Aspartate (NAA) in the cortex over 9 months

    The MRI scans will be acquired at baseline and 9-month follow-up using magnetic resonance spectroscopy (MRS).

    Time frame: 9 months

Secondary outcomes

  1. Disability progression as measured with Expanded Disability Status Scale (EDSS)

    Disability quantification using Expanded Disability Status Scale (EDSS) (evaluation performed at baseline, 3, 6 and 9 and 12 months). Disability progression will be determined as an increase of 1.0 points in EDSS if the baseline EDSS is \<5.5 and increase of 0.5 points in EDSS over the follow-up period if baseline EDSS is ≥5.5 points.

    Time frame: 1 year

  2. Symbol Digit Modality Test (SDMT)

    A neuropsychological assessment will be included using the Brief International Cognitive Assessment in MS (BICAMS) battery at baseline, and 9 months. Within the BICAMS battery, the cognitive performance will be evaluated using the Symbol Digit Modalities Test (SDMT)-measuring the correct number match within 90 sec ( higher is better- over 60 normal) . Group difference of 4-points in the SDMT test will be considered as significantly meaningful cognitive difference between the metformin-treated and placebo group.

    Time frame: 1 year

  3. Brief Visuospatial Memory Test ( BVMT)

    correct number of figures out of 6 - immediate and delayed after 20 min

    Time frame: 1 year

  4. California Verbal Learning Test (CVLT)

    Number of words remembered immediate and delayed out of a list of 16 words- (max is 16)

    Time frame: 1 year

  5. Conventional MRI outcomes

    Conventional MRI metrics: lesion burden: number and volume of lesions

    Time frame: 9 months

  6. Timed 25-foot walk test (T25FWT)

    Eval of gait, Change of 20% in the T25FWT (seconds) represents a meaningful change

    Time frame: 1 year

  7. 9-hole peg test (9HPT)

    9HPT measured in seconds performed at baseline, 3, 6 and 9 and 12 months. Change of 20% in the 9HPT (seconds) represents a meaningful change

    Time frame: 1 year

  8. Myelin water fraction (MWF)

    Non-conventional MRI metrics : myelin water fraction (MWF)

    Time frame: 9 months

Other outcomes

  1. Exploratory/tertiary MRI metrics

    Exploratory/tertiary MRI metrics assessment of cortical lesion burden using synthetic DIR sequence and perfusion-based imaging using arterial spin labeling (ASL).

    Time frame: 9 months

07

Study locations

1 of 1 sites recruiting
  • UBMD Neurolgy
    Buffalo, New York 14203, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

Of 49 non-industry phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 68. This study's planned 26 months is below that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 20 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jan 2027 → Dec 2027 and completion Jun 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
Jun 18, 2024
StartActual
Sep 24, 2025
Primary completionEst.
Dec 1, 2027was Jan 2027
CompletionEst.
Mar 1, 2028was Jun 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 1, 2027→Dec 1, 2027
Nov 6, 2026
Study completion
Jun 1, 2027→Mar 1, 2028
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Jan 1, 2027→Dec 1, 2027
    Study completion Jun 1, 2027→Mar 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06463743
Responsible party
Bianca Weinstock-Guttman (Professor of Neurology, State University of New York at Buffalo) — Principal investigator
First posted
Jun 18, 2024
Start date
Sep 24, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Kara Patrick
Contact
kpatrick@buffalo.edu
7168295037

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion